sefulness of Combination with Moisturizer in Nodular Prurigo Treatment

Not Applicable

• Conditions: odular Prurigo

• Registration Number: JPRN-UMIN000009384
• Lead Sponsor: Tokyo Medical and Dental University Department of Dermatology (main research institute)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-15
• Study Completion: 2014-12-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients with itchy condition other than nodular prurigo (2) Patients with ulcer, erosion and eczema caused by scratching in the target areas (3) Patients who are associated with severe (rash areas with strong inflammation are over 10% of BSA) or very severe form of atopic dermatitis (4) Patients with history of allergy to topical drugs (5) Patients with the following concurrent diseases: Clinically significant liver, kidney, heart, lungs or blood diseases that require hospitalization (6) Patients with kidney failure or kidney dysfunction (7) Patients who have participated in any clinical trial or clinical study within one month before clinical study starts (8) Patients who are judged to be inappropriate as a subject by the investigator or subinvestigator for other reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
(1) Evaluation of efficacy <Evaluation of severity> The severity of nodular prurigo will be evaluated in accordance with the 4 levels of criteria (none, mild, moderate and severe) for each indicator of the severity (keratinization, thickening, scraping and drying). <Evaluation of itch> The itch intensity of subjects will be evaluated in accordance with the visual analogue scale (VAS) and itch score (5 levels). (2) Evaluation of safety <Subjective and objective symptom> Following things occurred in the study will be studied. Adverse event description, seriousness (mild, moderate and severe), date of onset, action taken for adverse event, outcome (process and date of confirmation of outcome) and causal relationship to the study drug (Yes or No).